Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Novel bacteria-targeting nanoemulsions as photosensitizers for treating hospital-acquired pneumonia with antimicrobial photodynamic therapy
EF 2023-24
Résumé
With the rise of multidrug resistant bacterial strains, a new global health crisis is emerging. Hospital-acquired pneumonia is a lower respiratory tract infection that affects hospitalized patients at least 48 hours after admission and commonly showcases antibiotic resistance, resulting in a mortality rate of 50%. Novel methods must be developed to treat these serious infections, which result in over 1.5 million deaths annually. Antimicrobial photodynamic therapy (aPDT) is a promising alternative treatment which uses photosensitizers to absorb light and produce reactive oxygen species, killing nearby bacterial cells. aPDT is selective, non-invasive, and will not result in the development of resistance after repeated treatments. However, the lung surfactant, a mixture of phospholipids and proteins, coats the alveoli of the lungs and is a major obstacle preventing drugs from reaching bacterial cells, reducing aPDT efficacy. Therefore, we propose the formulation of a nano-sized drug that contains tightly packed photosensitizers and a bacteria-targeting group to bypass the lung surfactant and selectively enter bacterial cells. These formulations will be characterized and tested on bacteria commonly associated with hospital-acquired pneumonia to assess potency, safety, and interactions with the lung surfactant. aPDT parameters will be optimized for the greatest ablation of bacteria with minimal host toxicity. This study will play a significant role in improving our understanding of how to overcome the lung surfactant to direct drugs to their target cells and overcome antibiotic-resistant infections such as hospital-acquired pneumonia.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506422
Name
Liang Angela
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel bacteria-targeting nanoemulsions as photosensitizers for treating hospital-acquired pneumonia with antimicrobial photodynamic therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bacterial Pneumonia; Lung Surfactant; Nanoemulsion; Photodynamic Therapy; Photosensitizer
Abstract
With the rise of multidrug resistant bacterial strains, a new global health crisis is emerging. Hospital-acquired pneumonia is a lower respiratory tract infection that affects hospitalized patients at least 48 hours after admission and commonly showcases antibiotic resistance, resulting in a mortality rate of 50%. Novel methods must be developed to treat these serious infections, which result in over 1.5 million deaths annually. Antimicrobial photodynamic therapy (aPDT) is a promising alternative treatment which uses photosensitizers to absorb light and produce reactive oxygen species, killing nearby bacterial cells. aPDT is selective, non-invasive, and will not result in the development of resistance after repeated treatments. However, the lung surfactant, a mixture of phospholipids and proteins, coats the alveoli of the lungs and is a major obstacle preventing drugs from reaching bacterial cells, reducing aPDT efficacy. Therefore, we propose the formulation of a nano-sized drug that contains tightly packed photosensitizers and a bacteria-targeting group to bypass the lung surfactant and selectively enter bacterial cells. These formulations will be characterized and tested on bacteria commonly associated with hospital-acquired pneumonia to assess potency, safety, and interactions with the lung surfactant. aPDT parameters will be optimized for the greatest ablation of bacteria with minimal host toxicity. This study will play a significant role in improving our understanding of how to overcome the lung surfactant to direct drugs to their target cells and overcome antibiotic-resistant infections such as hospital-acquired pneumonia.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liang, Angela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~